Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392609 | 1.00 | LDHA (0.57) | LDHACYP11B1CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL18573277 | 0.96 | MMP3 (0.56) | LDHACYP11B1CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL21477415 | 0.81 | ABL1 (0.53) | LDHACYP11B1CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL28326772 | 0.80 | CYP11B1 (0.44) | CYP11B1CYP11B2HSD17B1HSD17B2IDO1 | |
| SCHEMBL1070654 | 0.80 | CCR1 (0.46) | HSD17B1HSD17B2MEN1KMT2ABCHE | |
| SCHEMBL30958843 | 0.80 | CCR1 (0.46) | HSD17B1HSD17B2MEN1KMT2ABCHE | |
| Phenol SCHEMBL27328542 | 0.79 | HSD17B1 (0.65) | LDHACYP11B1CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL2435669 | 0.78 | NPC1 (0.58) | CYP11B1CYP11B2HSD17B1HSD17B2MEN1 | |
| SCHEMBL8592351 | 0.78 | MEN1 (0.53) | HSD17B1HSD17B2MEN1KMT2ACYP2C8 | |
| SCHEMBL2435624 | 0.78 | MAPT (0.53) | HSD17B1HSD17B2MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248488-A | Novel heterocyclic amide piperidine derivative, preparation method thereof and application thereof in hypoglycemic drugs | 林剑雄 | 2021-08-13 | — | — | CN | claimed |
| EP-0440762-B1 | 5-OXY-2-PHENYLPYRIDINES AND LIQUID-CRYSTAL MATERIALS | HOECHST AG (DE) | 1996-07-17 | — | — | EP | claimed |
| US-5196141-A | Electrooptical display | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-03-23 | — | — | US | claimed |
| EP-0440771-A1 | 5-OXY-2-PHENYLAZINES AND MESOMORPHOUS MEDIUM | MERCK PATENT GmbH (DE) | 1991-08-14 | — | — | EP | claimed |
| EP-0440762-A1 | 5-OXY-2-PHENYLPYRIDINES AND LIQUID-CRYSTAL MATERIALS. | MERCK PATENT GMBH (DE) | 1991-08-14 | — | — | EP | claimed |
| WO-1991002722-A1 | 5-OXY-2-PHENYLPYRIDINES AND LIQUID-CRYSTAL MATERIALS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | claimed |
| WO-1991002726-A1 | 5-OXY-2-PHENYLAZINES AND MESOMORPHOUS MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113966324-B | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-0440771-A1 | 5-OXY-2-PHENYLAZINES AND MESOMORPHOUS MEDIUM | MERCK PATENT GmbH (DE) | 1991-08-14 | — | — | EP | disclosed |
| EP-0440771-A1 | 5-OXY-2-PHENYLAZINES AND MESOMORPHOUS MEDIUM | MERCK PATENT GmbH (DE) | 1991-08-14 | — | — | EP | disclosed |
| EP-0440762-A1 | 5-OXY-2-PHENYLPYRIDINES AND LIQUID-CRYSTAL MATERIALS. | MERCK PATENT GMBH (DE) | 1991-08-14 | — | — | EP | disclosed |
| WO-1991002722-A1 | 5-OXY-2-PHENYLPYRIDINES AND LIQUID-CRYSTAL MATERIALS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991002722-A1 | 5-OXY-2-PHENYLPYRIDINES AND LIQUID-CRYSTAL MATERIALS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991002726-A1 | 5-OXY-2-PHENYLAZINES AND MESOMORPHOUS MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991002726-A1 | 5-OXY-2-PHENYLAZINES AND MESOMORPHOUS MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LDHA 2432/4885CYP11B1 68/4885CYP11B2 86/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LDHA 2432/4885CYP11B1 68/4885CYP11B2 86/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LDHA 2432/4885CYP11B1 68/4885CYP11B2 86/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | LDHA 1056/4885CYP11B1 104/4885CYP11B2 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.